Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Piéra Fuzibet"'
Autor:
Hervé Watier, Gilles Paintaud, Piéra Fuzibet, Olivier Vittecoq, Emilie Ducourau, Céline Vignault, Thierry Lequerré, Xavier Le Loët, Philippe Goupille, Denis Mulleman, David Ternant
Publikováno v:
British Journal of Clinical Pharmacology. 79:286-297
Aims This study aimed at describing adalimumab pharmacokinetics (PK) and the concentration–effect relationship of adalimumab using pharmacokinetic–pharmacodynamic (PK–PD) modelling in patients with rheumatoid arthritis (RA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c69afeb0784227115e250495f649d508
https://doi.org/10.1111/bcp.12509
https://doi.org/10.1111/bcp.12509
Autor:
David, Ternant, Emilie, Ducourau, Piéra, Fuzibet, Céline, Vignault, Hervé, Watier, Thierry, Lequerré, Xavier, Le Loët, Olivier, Vittecoq, Philippe, Goupille, Denis, Mulleman, Gilles, Paintaud
Publikováno v:
British journal of clinical pharmacology. 79(2)
This study aimed at describing adalimumab pharmacokinetics (PK) and the concentration-effect relationship of adalimumab using pharmacokinetic-pharmacodynamic (PK-PD) modelling in patients with rheumatoid arthritis (RA).Adalimumab PK and PK-PD data we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::35794efe69ac6858e3081e06d6475d22
https://pubmed.ncbi.nlm.nih.gov/25223394
https://pubmed.ncbi.nlm.nih.gov/25223394
Autor:
David Ternant, Hervé Watier, Philippe Goupille, Emilie Ducourau, Piéra Fuzibet, Denis Mulleman, Thierry Lequerré, Gilles Paintaud, Olivier Vittecoq, Xavier Le Loët
Publikováno v:
Annals of the rheumatic diseases. 73(7)
Adalimumab, an anti-TNF-α monoclonal antibody, is effective in active rheumatoid arthritis (RA), but the response is highly variable between patients. Good responders have significantly higher adalimumab serum concentrations than non-responders.1 In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1807d79263bb499f35e81f9eff59aa
https://pubmed.ncbi.nlm.nih.gov/24550169
https://pubmed.ncbi.nlm.nih.gov/24550169
Autor:
Thierry Lequerré, Denis Mulleman, Piéra Fuzibet, David Ternant, Emilie Ducourau, Philippe Goupille, Olivier Vittecoq, X. Le Loët, Gilles Paintaud
Publikováno v:
Annals of the Rheumatic Diseases. 72:A427.1-A427
Background Adalimumab, an anti-TNF-α monoclonal antibody, is effective in active rheumatoid arthritis (RA). There is a relationship between adalimumab concentration and clinical response but it has never been quantified individually. Objectives To d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c78b808f10958f6ee544396498d0ebef
https://doi.org/10.1136/annrheumdis-2013-eular.1292
https://doi.org/10.1136/annrheumdis-2013-eular.1292
Autor:
Piéra Fuzibet, Thierry Lequerré, Emilie Ducourau, David Ternant, Denis Mulleman, Philippe Goupille, Gilles Paintaud, X. Le Loët, Olivier Vittecoq
Publikováno v:
Annals of the Rheumatic Diseases. 72:A229.1-A229
Background Adalimumab, an anti-TNF-α monoclonal antibody, is effective in active rheumatoid arthritis (RA). Subcutaneous injections of adalimumab lead to highly variable trough concentrations between patients [[1][1]] that may partly explain the var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40f38c9ef607de6e3d56639edd5f7d21
https://doi.org/10.1136/annrheumdis-2013-eular.721
https://doi.org/10.1136/annrheumdis-2013-eular.721